Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Enanta Pharmaceuticals (ENTA)
NASDAQ:ENTA
Enanta Pharmaceuticals (ENTA) Stock Price & Analysis
154 Followers
ENTA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.08 - $20.04
Previous Close$16.54
Volume157.35K
Average Volume (3M)177.04K
Market Cap
$350.31M
Enterprise Value$38.65M
Total Cash (Recent Filing)$337.15M
Total Debt (Recent Filing)$25.49M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Aug 06, 2024EPS Estimate
-$1.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.25
Shares Outstanding21,179,400
10 Day Avg. Volume233,472
30 Day Avg. Volume177,037
Standard Deviation0.16
R-Squared0.04
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.32
Price to Sales (P/S)3.19
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.49
Enterprise Value/Gross Profit0.49
Enterprise Value/Ebitda-0.29
Forecast
1Y Price Target
$23.40Price Target Upside44.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Enanta Pharmaceuticals News
PremiumCompany Announcements
Enanta Pharmaceuticals Shareholders Affirm Management Direction
Bulls Say, Bears Say
Bulls Say
Financial StabilityEnanta ended with cash and cash equivalents of ~$300M, which management expects to provide sufficient cash runway through F3Q27.
Immunology ExpansionNew oral KIT inhibitor program leads expansion into immunology.
RSV ProgramRSVPEDs study is finalizing enrollment, setting up an expected readout with meaningful upside potential and an important influence on future ambitions in RSV.
Bears Say
Clinical TrialsThere is skepticism around the Phase 2b RSVHR study program given the previous Phase 2 trial failure in otherwise healthy adults.
Financial PerformanceEnanta reported total royalty revenues for Mavyret in HCV that were approximately 3% below the estimate.
Operational CostsOperating expenses were a bit higher than expected.
---
Ownership Overview
37.25% Insiders
18.05% Mutual Funds
10.27% Other Institutional Investors
34.42% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ENTA FAQ
What was Enanta Pharmaceuticals’s price range in the past 12 months?
Enanta Pharmaceuticals lowest stock price was $8.08 and its highest was $20.04 in the past 12 months.
What is Enanta Pharmaceuticals’s market cap?
Currently, no data Available
When is Enanta Pharmaceuticals’s upcoming earnings report date?
Enanta Pharmaceuticals’s upcoming earnings report date is Aug 06, 2024 which is in 20 days.
How were Enanta Pharmaceuticals’s earnings last quarter?
Enanta Pharmaceuticals released its earnings results on May 06, 2024. The company reported -$1.47 earnings per share for the quarter, missing the consensus estimate of -$1.336 by -$0.134.
Is Enanta Pharmaceuticals overvalued?
According to Wall Street analysts Enanta Pharmaceuticals’s price is currently Undervalued.
Does Enanta Pharmaceuticals pay dividends?
Enanta Pharmaceuticals does not currently pay dividends.
What is Enanta Pharmaceuticals’s EPS estimate?
Enanta Pharmaceuticals’s EPS estimate is -$1.43.
How many shares outstanding does Enanta Pharmaceuticals have?
Enanta Pharmaceuticals has 21,179,400 shares outstanding.
What happened to Enanta Pharmaceuticals’s price movement after its last earnings report?
Enanta Pharmaceuticals reported an EPS of -$1.47 in its last earnings report, missing expectations of -$1.336. Following the earnings report the stock price went down -10.274%.
Which hedge fund is a major shareholder of Enanta Pharmaceuticals?
Among the largest hedge funds holding Enanta Pharmaceuticals’s share is Farallon Capital Management, L.L.C.. It holds Enanta Pharmaceuticals’s shares valued at 37M.
---
Enanta Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.40 (44.89% Upside)
$23.40 (44.89% Upside)
Hedge Fund Trend
Increased
By 56.6K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.94%
12-Months-Change
Fundamentals
Return on Equity
-60.50%
Trailing 12-Months
Asset Growth
26.68%
Trailing 12-Months
Company Description
Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
---
ENTA Company Deck
---
ENTA Earnings Call
Q2 2024
0:00 / 0:00
---
ENTA Stock 12 Month Forecast
Average Price Target
$23.40
▲(44.89% Upside)
Technical Analysis
Assembly Biosciences
―
Intra-Cellular Therapies
―
Kala Pharmaceuticals
―
MacroGenics
―
Best Analysts Covering ENTA
1 Year
1 Year Success Rate
9/17 ratings generated profit
1 Year Average Return
+10.73%
assigned a buy rating 26 days ago
Copying Liisa Bayko's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of +10.73% per trade.
---